By submitting this form, you consent to All About Obesity (AAO) contacting you for this purpose. We’ll only store and process your personal data to administer your account and provide the information you request from us. From time to time, we’d like to contact you about our services, as well as other content that may be helpful for you e.g. new blog posts on obesity, so please check the box above if you’d like to sign up to our newsletter. You can unsubscribe from these communications or withdraw your consent at any time. For more information on how to unsubscribe, our privacy practices, and how we’re committed to protecting and respecting your privacy, please see our Privacy Policy.
Share your experiences of living with, working with and understanding of those, living with obesity, with us, this will help us shape and prioritise what we do.
We want to ensure that All About Obesity adds value, so tell us what you would like to see, want more of and don’t like. All media requests please contact us here.
Email address – admin@allaboutobesity.org
Mounjaro is the brand name for tirzepatide, a weekly injectable prescription-only medication for the treatment of obesity. It mimics natural hormones in the gut to help
In August 2025, the manufacturer of Mounjaro (tirzepatide) announced a UK price increase, significantly impacting private patients who rely on this medication for effective weight management. While NHS patients will not be affected
Sarah Le Brocq, had the opportunity to film a series of exercise and mobility videos with sport scientist and personal trainer, Luke Worthington. The resulting
